Cargando…
Measuring quality of life impairment in skeletal muscle channelopathies
BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492909/ https://www.ncbi.nlm.nih.gov/pubmed/22607270 http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x |
_version_ | 1782249187555934208 |
---|---|
author | Sansone, V A Ricci, C Montanari, M Apolone, G Rose, M Meola, G |
author_facet | Sansone, V A Ricci, C Montanari, M Apolone, G Rose, M Meola, G |
author_sort | Sansone, V A |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized QoL) and SF-36 questionnaires. METHODS: We administered INQoL and SF-36 to 66 Italian patients with SMC (26: periodic paralysis, 36: myotonia congenita and 4: Andersen-Tawil) and compared the results in 422 patients with myotonic dystrophies (DM1: 382; and DM2: 40). RESULTS: (i) INQoL index in SMC is similar to that in DMs (P = 0.79). (ii) Patients with myotonia congenita have the worst perception of QoL. (iii) Myotonia has the most detrimental effect on patients with myotonia congenita, followed by patients with DM2 and then by patients with DM1 and hyperkalemic periodic paralysis. (iv) Pain is a significant complaint in patients with myotonia congenita, hypokalemic periodic paralysis and DM2 but not in DM1. (v) Fatigue has a similar detrimental effect on all patient groups except for patients with hyperkalemic periodic paralysis in whom muscle weakness and myotonia more than fatigue affect QoL perception. (vi) Muscle symptoms considered in INQoL correlate with physical symptoms assessed by SF-36 (R from −0.34 to −0.76). CONCLUSIONS: QoL perception in patients with SMC is similar to that of patients with DMs, chronic multisystem disabling conditions. Our results provide information to target treatment and health care of these patients. The sensitivity of INQoL to changes in QoL in the SMC needs to be further explored in longitudinal studies. |
format | Online Article Text |
id | pubmed-3492909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-34929092012-11-09 Measuring quality of life impairment in skeletal muscle channelopathies Sansone, V A Ricci, C Montanari, M Apolone, G Rose, M Meola, G Eur J Neurol Original Articles BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized QoL) and SF-36 questionnaires. METHODS: We administered INQoL and SF-36 to 66 Italian patients with SMC (26: periodic paralysis, 36: myotonia congenita and 4: Andersen-Tawil) and compared the results in 422 patients with myotonic dystrophies (DM1: 382; and DM2: 40). RESULTS: (i) INQoL index in SMC is similar to that in DMs (P = 0.79). (ii) Patients with myotonia congenita have the worst perception of QoL. (iii) Myotonia has the most detrimental effect on patients with myotonia congenita, followed by patients with DM2 and then by patients with DM1 and hyperkalemic periodic paralysis. (iv) Pain is a significant complaint in patients with myotonia congenita, hypokalemic periodic paralysis and DM2 but not in DM1. (v) Fatigue has a similar detrimental effect on all patient groups except for patients with hyperkalemic periodic paralysis in whom muscle weakness and myotonia more than fatigue affect QoL perception. (vi) Muscle symptoms considered in INQoL correlate with physical symptoms assessed by SF-36 (R from −0.34 to −0.76). CONCLUSIONS: QoL perception in patients with SMC is similar to that of patients with DMs, chronic multisystem disabling conditions. Our results provide information to target treatment and health care of these patients. The sensitivity of INQoL to changes in QoL in the SMC needs to be further explored in longitudinal studies. Blackwell Publishing Ltd 2012-11 2012-05-19 /pmc/articles/PMC3492909/ /pubmed/22607270 http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x Text en European Journal of Neurology © 2012 European Federation of Neurological Societies http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Original Articles Sansone, V A Ricci, C Montanari, M Apolone, G Rose, M Meola, G Measuring quality of life impairment in skeletal muscle channelopathies |
title | Measuring quality of life impairment in skeletal muscle channelopathies |
title_full | Measuring quality of life impairment in skeletal muscle channelopathies |
title_fullStr | Measuring quality of life impairment in skeletal muscle channelopathies |
title_full_unstemmed | Measuring quality of life impairment in skeletal muscle channelopathies |
title_short | Measuring quality of life impairment in skeletal muscle channelopathies |
title_sort | measuring quality of life impairment in skeletal muscle channelopathies |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492909/ https://www.ncbi.nlm.nih.gov/pubmed/22607270 http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x |
work_keys_str_mv | AT sansoneva measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT riccic measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT montanarim measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT apoloneg measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT rosem measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT meolag measuringqualityoflifeimpairmentinskeletalmusclechannelopathies AT measuringqualityoflifeimpairmentinskeletalmusclechannelopathies |